✦ LIBER ✦

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

✍ Scribed by Y. TOMIYAMA; Y. MIYAKAWA; S. OKAMOTO; S. KATSUTANI; A. KIMURA; Y. OKOSHI; H. NINOMIYA; H. KOSUGI; S. NOMURA; K. OZAKI; Y. IKEDA; T. HATTORI; K. KATSURA; Y. KANAKURA

Book ID: 114754742
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 351 KB
Volume: 10
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2012.04695.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of eltrombopag in Ja

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study

✍ Takumi Kawaguchi, Atsumasa Komori, Masataka Seike, Shigetoshi Fujiyama, Hiroshi 📂 Article 📅 2012 🏛 Springer Japan 🌐 English ⚖ 324 KB

Thrombocytopenia Induced by Imatinib Mes

Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?

✍ Keisuke Miyazawa; Jiroh Nishimaki; Tomoko Katagiri; Goro Sashida; Nahoko Shoji; 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 113 KB